



NEWS RELEASE for November 20, 2007

**BIOLASE TO PRESENT AT THE LAZARD CAPITAL
MARKETS HEALTHCARE CONFERENCE IN NEW YORK CITY**

IRVINE, CA (November 20, 2007) . . . BIOLASE Technology, Inc. (NASDAQ:BLTI), the world's leading dental laser company, announced today that Interim CEO Federico Pignatelli and CFO Richard L. Harrison are scheduled to make an investor presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference on Wednesday, November 28 at 1:30 pm Eastern Time. The conference is being held November 27-28 at The New York Palace in New York City.

The presentation will be accessible by live web cast on the investor relations section of the BIOLASE web site at www.biolase.com. A replay of the web cast will be available on the BIOLASE web site for 30 days.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (<http://www.biolase.com>), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: Richard L. Harrison, Executive Vice President and CFO of BIOLASE Technology, Inc., +1-949-361-1200; or Jill Bertotti, of Allen & Caron, +1-949- 474-4300.

###